Navigation Links
Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
Date:10/3/2011

logic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer cells, for the treatment of acute myeloid leukemia and solid tumors.

The Company recently completed a $25.8 million round of financing and is using the proceeds to advance its pipeline, including funding Phase II double-blind, placebo controlled trial of CNDO-201 for the treatment of Crohn's Disease scheduled for initiation in early 2012 and a Phase I/II dose escalation and expansion trial of CNDO-109 for the treatment of relapsed Acute Myeloid Leukemia (AML) planned for 2012.  Each of these drugs is a novel therapy that has achieved clinical proof-of-concept in indications with unmet medical needs.

Forward-Looking StatementsThis press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Such statements include, but are not limited to, any statements relating to the Company's product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated risks relating to the results of research and development activities, uncertainties relating to preclinical and clinical testing, financing and strategic agreements and relationships, the early stage of products under development, our need for substantial additional funds, government regulation, patent and intellectual property matters; and competition, as well as other risks described in our SEC filings.  We expressly disclaim any obligation or undertaking to release publicly any updates or r
'/>"/>

SOURCE Coronado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
2. Coronado Biosciences Closes $25.8M in Series C Financing
3. Coronado Biosciences Files to Become a Public Reporting Company
4. Coronado Biosciences to Present at the Rodman & Renshaw Annual Global Investment Conference
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
7. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
11. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  Armada Health Care (Armada), ... (GPO), is pleased to announce an agreement with ... host of innovative specialty pharmacy patient program offerings. ... therapy management services to specialty patients via Armada,s ... Aurora will use the OTM platform as ...
(Date:8/21/2014)... /CNW/ - Bedrocan Cannabis Corp., previously Bedrocan Canada Inc. ... Board of Directors, enhancing executive oversight and strengthening ... leading licensed producer of medicinal cannabis in ... years, experience in producing and supplying government-regulated pharmaceutical-grade ... As previously announced in a ...
(Date:8/21/2014)... Pa. , Aug. 21, 2014   ... ), a specialty biopharmaceutical company, today announced positive ... of collagenase clostridium histolyticum (or CCH) for the ... as cellulite. In the Phase 2a trial, all ... and high (0.84mg)) showed an improvement in the ...
Breaking Medicine Technology:Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7
... (Nasdaq: DNDN ) today announced that the ... convertible senior notes due January 15, 2016 (the "Notes") ... to purchase an additional $80 million aggregate principal amount ... exercise of the overallotment option, resulted in net proceeds ...
... Hospira, Inc. (NYSE: HSP ), the ... Food and Drug Administration (FDA) approval of Topotecan Injection, ... in the United States. The medication is a generic ... more than $140 million. Hospira,s topotecan is indicated for ...
Cached Medicine Technology:Dendreon Announces Exercise and Closing of Overallotment Option 2Hospira Announces FDA Approval of Topotecan Injection 2
(Date:8/21/2014)... to be elicited by T-type calcium channels in ... regulate influxes of calcium. These channels enable thalamic ... the neurons to enter a hyper-excited state. , ... firing and absence seizures, the researchers conducted an ... gene targeting techniques to delete the T-type calcium ...
(Date:8/21/2014)... 2014 The "North ... Devices Market by Angioplasty Balloon (Plain/Old, ... OCT), IVC Filter (Retrievable), Endovascular Stent ... and studies the major market drivers, ... and Canada. , Browse 108 market ...
(Date:8/21/2014)... August 21, 2014 mynt welcomes industry ... promoters to join its growing company. Since its pre-launch ... in product sales and continues to gain momentum leading ... , Rob and Tiffanie came into network marketing by ... a number of network marketing companies. Tiffanie needed help ...
(Date:8/21/2014)... One of the emerging trends in the market ... This increases the availability and accessibility of these products to ... Ostomy Care Accessories market to grow at a ... the report, the Global Ostomy Care Accessories market is driven ... the major drivers. The number of procedures is increasing owing ...
(Date:8/21/2014)... Australian scientists say a commercially available ... been used to successfully fight mesothelioma in lab mice. ... new research. Click here to read it now. ... treated mesothelioma cells with the S. aureus ... while simultaneously stimulating a stronger anti-tumor response in healthy ...
Breaking Medicine News(10 mins):Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 4Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 5Health News:Industry Leaders Rob and Tiffanie Moffitt Join mynt 2Health News:Ostomy Care Accessories Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 2Health News:Ostomy Care Accessories Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 3Health News:Ostomy Care Accessories Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 4Health News:Study Finds Bacteria Compound Shrinks Mesothelioma Tumors, According to Surviving Mesothelioma 2
... is a primary long-term complication among premature infants suffering ... risk for pulmonary hypertension and impaired growth, and ... neurological problems. ,A new study finds premature ... with inhaled nitric oxide. ,Researchers from the University ...
... have lasted for less than three months. ,A new ... exercise sheet// handouts, and telephone follow-up calls may help ... ,Researchers from Indiana University developed a self-management program for ... focuses on boosting confidence in order to increase their ...
... a step forward in their search for a cure for ... the spleen appear to develop into insulin producing //pancreatic islet ... with diabetes. ,The latest research is a follow ... advanced type 1 diabetes in mice. The new research focuses ...
... New research shows screening newborns for biochemical genetic disorders ... parents. However, researchers say false-positive screening results may increase ... genetic disorders required a separate test, but now, doctors ... just one sample of blood by using a device ...
... transplanting chimpanzee organs into humans in need of an organ ... survived 20 days. // Since then, doctors have continued to ... cells to treat various diseases, all with varying degrees of ... -- also known as xenotransplantation. ,Dick Beyer ...
... Arthritis is a common health problem worldwide. Both osteoarthritis ... patients. There is no cure for arthritis and no ... new study could help lead doctors towards a drug ... the molecular pathway and an enzyme that play a ...
Cached Medicine News:Health News:Screening Newborns Questioned 2Health News:Animals Can give us a second chance at life 2
Our soft guedel airway is clear and has a color coded bite block. Airway has a smooth finish and is Latex Free. Recommended for single use. Non-Sterile....
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
... Endotracheal Tube Kits (silicone) Magill, ... includes a SidePort™ AutoControl™ airway connector, ... mm ISO connector., ,The wire ... helping to ensure an open airway., ...
... Portex® Blue Line® uncuffed ... Magill or Murphy styles, in ... ,Blue Line® adult and pediatric ... from implant-tested polyvinyl chloride with ...
Medicine Products: